drugset / Trial / NCT00433277

Autoimmunity in Retinitis Pigmentosa

NCT00433277

Non-randomizedSingle-groupOpen-label

Summary

Using local immune suppression, the trial seeks evidence for the hypothesis that autoimmunity plays a role in the pathomechanism of retinitis pigmentosa.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 0.5 % Other

Indications